Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
proton pump inhibitor |
| gptkbp:approvedBy |
1995
|
| gptkbp:ATCCode |
A02BC03
|
| gptkbp:availableOn |
capsule
orally disintegrating tablet granules for oral suspension |
| gptkbp:bioavailability |
80-90%
|
| gptkbp:brand |
Prevacid
Takepron Zoton |
| gptkbp:CASNumber |
103577-45-3
|
| gptkbp:category |
gptkb:pharmacy
gastroenterology digestive system drug |
| gptkbp:chemicalFormula |
C16H14F3N3O2S
|
| gptkbp:contraindication |
hypersensitivity to lansoprazole
|
| gptkbp:discoveredBy |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:drugInteraction |
may interact with atazanavir
may interact with digoxin may interact with ketoconazole may interact with warfarin |
| gptkbp:eliminationHalfLife |
1.5 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:genericAvailable |
yes
|
| https://www.w3.org/2000/01/rdf-schema#label |
lansoprazole
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits H+/K+ ATPase in gastric parietal cells
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
369.36 g/mol
|
| gptkbp:patentExpired |
yes
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:proteinBinding |
97%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea abdominal pain constipation headache |
| gptkbp:usedFor |
treatment of peptic ulcer disease
treatment of Zollinger-Ellison syndrome treatment of gastroesophageal reflux disease treatment of erosive esophagitis treatment of Helicobacter pylori infection (in combination therapy) |
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:CYP3A4
|
| gptkbp:bfsLayer |
5
|